Galderma Group AG (CH:GALD)
:GALD
Want to see CH:GALD full AI Analyst Report?
GALD Stock Chart & Stats
CHF156.85
-CHF8.02(-7.15%)
At close: 4:00 PM EST
CHF156.85
-CHF8.02(-7.15%)
Day’s Range― - ―
52-Week RangeCHF110.60 - CHF176.55
Previous CloseN/A
Volume230.69K
Average Volume (3M)337.59K
Market Cap
CHF40.79B
Enterprise ValueCHF52.72B
Total Cash (Recent Filing)CHF780.00M
Total Debt (Recent Filing)CHF2.75B
Price to Earnings (P/E)80.4
Beta0.77
Next Earnings
Jul 23, 2026Next Dividend Ex-DateN/A
Dividend Yield0.09%
Share Statistics
EPS (TTM)2.69
Shares Outstanding237,897,630
10 Day Avg. Volume210,266
30 Day Avg. Volume337,589
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)5.94
Price to Sales (P/S)9.24
P/FCF Ratio46.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF190.78Price Target Upside21.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)4.64
Revenue Forecast (FY)CHF6.31B
Bulls Say, Bears Say
Bulls Say
High Gross Margins & ProfitabilitySustained gross margins near 67–70% and an operating margin expansion (EBIT rising to ~16.4% by 2025) indicate durable unit economics and pricing power. This margin base supports reinvestment, resiliency to cost pressure, and underpins lasting cash generation if product mix remains stable.
Stronger Free Cash Flow GenerationA step-change to ~1.03B FCF in 2025 improves financial flexibility for capex, R&D, dividends and debt reduction. FCF at ~87% of net income signals cash quality behind reported profits, making capital allocation more sustainable over the medium term if operating performance holds.
Material DeleveragingMarked reduction in leverage materially improves balance-sheet resilience and lowers interest burden, enabling strategic flexibility. This structural repair enhances capacity for M&A, R&D investment or dividend policy adjustments while reducing refinancing and covenant risks over the coming quarters.
Bears Say
Uneven Revenue MomentumTop-line weakening while margins drove profit gains signals growth fragility; earnings improvements may be driven more by cost or mix effects than sustainable demand. If revenue growth does not reaccelerate, margin-driven profit gains could be harder to maintain long term.
Sizable Absolute Debt LevelAlthough leverage ratios improved, a large nominal debt stock (~2.75B) still constrains flexibility if growth or cash flow weakens. Higher absolute debt raises exposure to interest-rate moves and refinancing needs, which could limit capital allocation under adverse scenarios.
Historic Cash Flow VolatilityPrior years showed negative or inconsistent cash generation, so the 2025 improvement may not reflect a durable trend yet. Historical swings raise execution risk: sustaining investments, dividends or further debt paydown depends on proving consistent multi-year cash conversion.
Galderma Group AG News
GALD FAQ
What was Galderma Group AG’s price range in the past 12 months?
Galderma Group AG lowest stock price was CHF110.60 and its highest was CHF176.55 in the past 12 months.
What is Galderma Group AG’s market cap?
Galderma Group AG’s market cap is CHF40.79B.
When is Galderma Group AG’s upcoming earnings report date?
Galderma Group AG’s upcoming earnings report date is Jul 23, 2026 which is in 29 days.
How were Galderma Group AG’s earnings last quarter?
Galderma Group AG released its earnings results on Mar 05, 2026. The company reported CHF1.602 earnings per share for the quarter, beating the consensus estimate of CHF1.243 by CHF0.358.
Is Galderma Group AG overvalued?
According to Wall Street analysts Galderma Group AG’s price is currently Undervalued.
Does Galderma Group AG pay dividends?
Galderma Group AG pays a Notavailable dividend of CHF0.35 which represents an annual dividend yield of 0.09%. See more information on Galderma Group AG dividends here
What is Galderma Group AG’s EPS estimate?
Galderma Group AG’s EPS estimate is 1.
How many shares outstanding does Galderma Group AG have?
Galderma Group AG has 237,897,630 shares outstanding.
What happened to Galderma Group AG’s price movement after its last earnings report?
Galderma Group AG reported an EPS of CHF1.602 in its last earnings report, beating expectations of CHF1.243. Following the earnings report the stock price went up 6.975%.
Which hedge fund is a major shareholder of Galderma Group AG?
Currently, no hedge funds are holding shares in CH:GALD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galderma Group AG
Galderma Group AG is a company primarily focused on the cosmetics sector. Its operations are structured around three distinct business segments: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology.
GALD Stock 12 Month Forecast
Average Price Target
CHF190.78
▲(21.63% Upside)
Technical Analysis
Options Prices
Currently, No data available
---